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Abstract
 
Hypoxia-induced VEGF governs both physiological retinal vascular development and patho-
logical retinal neovascularization. In the current paper, the mechanisms of physiological and
pathological neovascularization are compared and contrasted. During pathological neovascular-
ization, both the absolute and relative expression levels for VEGF
 
164
 
 increased to a greater degree
than during physiological neovascularization. Furthermore, extensive leukocyte adhesion was
observed at the leading edge of pathological, but not physiological, neovascularization. When a
VEGF
 
164
 
-specific neutralizing aptamer was administered, it potently suppressed the leukocyte ad-
hesion and pathological neovascularization, whereas it had little or no effect on physiological
neovascularization. In parallel experiments, genetically altered VEGF
 
164
 
-deficient (VEGF
 
120/188
 
)
mice exhibited no difference in physiological neovascularization when compared with wild-type
(VEGF
 

 
/
 

 
) controls. In contrast, administration of a VEGFR-1/Fc fusion protein, which blocks
all VEGF isoforms, led to significant suppression of both pathological and physiological neovas-
cularization. In addition, the targeted inactivation of monocyte lineage cells with clodronate-
liposomes led to the suppression of pathological neovascularization. Conversely, the blockade of
T lymphocyte–mediated immune responses with an anti-CD2 antibody exacerbated patho-
logical neovascularization. These data highlight important molecular and cellular differences be-
tween physiological and pathological retinal neovascularization. During pathological neovascu-
larization, VEGF
 
164
 
 selectively induces inflammation and cellular immunity. These processes
provide positive and negative angiogenic regulation, respectively. Together, new therapeutic ap-
proaches for selectively targeting pathological, but not physiological, retinal neovascularization
are outlined.
Key words: retina • angiogenesis • VEGF • leukocyte • immunity
 
Introduction
 
Retinal neovascular diseases such as retinopathy of prema-
turity and proliferative diabetic retinopathy are the major
causes of neonatal and adult blindness. During both physio-
logical retinal vascular development (1) and pathological
proliferative retinopathy (2), new blood vessel growth is
regulated by vascular endothelial growth factor (VEGF), a
hypoxia-induced endothelial cell–specific mitogen pro-
duced in ischemic retinal cells. Although both types of
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neovascularization stem from retinal ischemia, there is an
essential difference in the direction of vessel growth dur-
ing physiological and pathological neovascularization. In
the former, new vessels extend from the optic disc toward
the peripheral avascular retina, and follow the guidance of
VEGF-expressing retinal astrocytes (2). During pathologi-
cal neovascularization, although ischemic retinal astro-
cytes and neurons express VEGF (1), the new vessels in-
vade the vitreous cavity. This ectopic neovascularization
leads to fibrovascular proliferation, resulting in vision-
threatening complications, such as vitreous hemorrhage and
traction retinal detachment. Coincident with the patho-
logical neovascularization, the once-vascularized and newly
ischemic central areas of the retina are reinvested with
normal-appearing blood vessels, a process termed “revas-
cularization.” When reagents that block all VEGF iso-
forms are used, this compensatory intraretinal revascu-
larization is suppressed together with the pathological
neovascularization (3). Thus, ophthalmologists await the
establishment of a new therapy that selectively targets
pathological neovascularization, while sparing compensa-
tory revascularization.
The current paper demonstrates that the differential ex-
pression of VEGF
 
164
 
 results in leukocyte adhesion at the
leading edge of pathological, but not physiological, neovas-
cularization. Furthermore, differential functions for the
various leukocyte subpopulations recruited to the sites of
neovascularization are demonstrated here. As a result, new
mechanistic differences are uncovered at the molecular and
cellular levels between the physiological and pathological
neovascularization.
 
Materials and Methods
 
Rat Model of Proliferative Retinopathy.
 
All animal experiments
followed the Association for Research in Vision and Ophthal-
mology guidelines and were approved by the Animal Care Com-
mittee of Massachusetts Eye and Ear Infirmary. Long-Evans rats
(Charles River Laboratories) were used. Postnatal day zero (P0)
rats with their nursing mothers were maintained for 10 full days
in 80% oxygen, interrupted daily by 30 min in room air followed
by a progressive return to 80% oxygen, to induce an avascular
retina. On P10 (D0), they were placed in room air for an addi-
tional 7 d (D7) to induce retinal neovascularization. 
 
ELISA for VEGF.
 
After sacrifice with an overdose of anes-
thesia, the eyes were immediately enucleated. The retina was
carefully isolated, placed into 150 
 

 
l of lysis buffer, and sonicated.
The lysate was centrifuged at 14,000 rpm for 15 min at 4
 

 
C, and
the VEGF levels in the supernatant were determined with the
Quantikine mouse VEGF ELISA kit (R&D Systems) according to
manufacturer’s protocol. The assay recognizes all VEGF isoforms. 
 
Reverse Transcription (RT)–PCR for VEGF.
 
Total RNA was
isolated from the retina and peripheral monocytes with TRIzol
reagent (Life Technologies), and cDNA was produced using
reverse transcriptase (SuperScript II; Invitrogen). The primer
sequences for GAPDH and rat VEGF were 5
 

 
-CCATG-
GAGAAGGCTGGGG-3
 

 
 (sense) and 5
 

 
-CAAAGTTGTCA-
TGGATGACC-3
 

 
 (antisense) for GAPDH and 5
 

 
-ACCTC-
CACCATGCCAAGT-3
 

 
 (sense) and 5
 

 
-TAGTTCCCGAA-
ACCCTGA-3
 

 
 (antisense) for VEGF. Analysis of RT-PCR data
 
was performed using the intensity ratios of VEGF
 
164
 
/VEGF
 
120
 
 in
each lane.
 
Lectin Labeling of Retinal Vasculature and Adherent Leukocytes.
 
The retinal vasculature and adherent leukocytes were imaged by
perfusion-labeling with FITC-coupled Concanavalin A lectin
(Con A; Vector Laboratories) as described previously (4). The flat
mounts were imaged using two epifluorescence microscopes
(models DM RXA and MZ FLIII; Leica), each possessing a dif-
ferent range of magnification.
 
Intravitreous Injection of Anti-VEGF
 
165
 
 Aptamer (EYE001).
 
Af-
ter deep anesthesia, an eyelid fissure was created with a fine blade
to expose the eyeball. Intravitreous injections were performed by
inserting a 33-gauge double caliber needle (Ito Corporation) un-
der an operating microscope. Animals received intravitreous in-
jections of 1 
 

 
l of sterile PBS containing 0.5 nmol of a pegylated
anti-VEGF
 
165
 
 aptamer (EYE001; Eyetech Pharmaceuticals) or
polyethylene glycol (PEG) control. Retinal neovascularization
and leukocyte adhesion were evaluated 7 d after administration in
D0 (P10) retinopathy rats and P3 normal neonates.
The anti-VEGF
 
165
 
 aptamer is an oligonucleotide that binds to
the exon 7–encoded domain of human VEGF
 
165
 
 protein with
high specificity and affinity. The oligonucleotide is conjugated
to a 40-kD PEG moiety to increase its half-life. The aptamer
does not bind to VEGF
 
120(121)
 
 and efficiently neutralizes VEGF
 
164
 
in rats.
 
Intravitreous Injection of a VEGFR-1/Fc Fusion Protein.
 
Ani-
mals received 1-
 

 
l intravitreous injections of sterile PBS contain-
ing 1 
 

 
g of a mouse VEGFR-1/Fc chimera (R&D Systems) or
an isotype Fc control (R&D Systems). The fusion protein blocks
all VEGF isoforms. A maximal effect dosage (1 
 

 
g per eye) was
determined and used for comparison with the maximal effect dos-
age of the anti-VEGF
 
165
 
 aptamer.
 
Generation of VEGF
 
164
 
-deficient (VEGF
 
120/188
 
) Mice.
 
VEGF
 

 
/120
 
male and VEGF
 

 
/188
 
 female mice, generated previously (5) via
targeted mutagenesis with Cre/
 
loxP
 
–mediated site-specific re-
combination in embryonic stem cells, were mated to each other.
Sired neonates were genotyped as described previously (5) to se-
lect VEGF
 
164
 
-deficient (VEGF
 
120/188
 
) mice and age-matched
wild-type control (VEGF
 

 
/
 

 
) mice for analysis at P10.
 
CD13, CD8, and CD25 Immunofluorescence.
 
Adherent leu-
kocytes were labeled with rhodamine-coupled Con A as de-
scribed above in the fourth paragraph of Materials and Methods.
Retinal flat mounts were permeabilized with 0.5% Triton X
(Sigma-Aldrich) in PBS for 24 h and nonspecific binding was
blocked with 1% BSA. The retinas were incubated with a FITC-
conjugated mouse monoclonal antibody against CD13 (clone
WM15, 1:100; Research Diagnostics), CD8 (clone OX-8, 1:100;
Research Diagnostics), or CD25 (clone OX-39, 1:100; Research
Diagnostics) overnight at 4
 

 
C.
 
Isolation and Hypoxic Stimulation of Monocytes.
 
Blood was
drawn from D7 rats with retinopathy before sacrifice. The mono-
cytes were purified by positive selection via magnetic cell sorting
(MACS) using MicroBeads conjugated with a monoclonal anti–
rat MHC-II antibody (clone OX-6; Miltenyi Biotec) according
to the manufacturer’s instructions. The isolated monocytes were
seeded at a concentration of 2.5 
 

 
 10
 
6
 
 cells per dish and stimu-
lated for 8 h at 37
 

 
C with 1 or 21% oxygen in a humidified air-
tight chamber (Modular Incubator Chamber; Billups-Rothen-
berg). The incubated cells were collected and processed for
RT-PCR for VEGF as described above in the third paragraph of
Materials and Methods.
 
Intravitreous Administration of Clodronate-liposomes.
 
Clodro-
nate (dichloromethylene diphosphonate) was a gift from Roche
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Diagnostics. Animals with retinopathy received 1-
 

 
l intravitreous
injections of clodronate- or PBS-liposomes on D0 (P10). The de-
gree of retinal neovascularization was evaluated 7 d later.
 
Systemic CD2 Blockade.
 
Rats with retinopathy received intra-
peritoneal injections of 5 mg/kg/day of a mouse anti-rat CD2
neutralizing antibody (clone OX-34; Research Diagnostics) or a
mouse isotype nonimmune antibody (R&D Systems). The re-
agents were injected for seven consecutive days before evaluation
on D7 (P17).
 
Endothelial and Lymphocyte Cocultures.
 
Blood was drawn from
D7 rats with retinopathy and age-matched (P17) controls before
sacrifice. Cytotoxic T lymphocytes (CTLs) were purified by pos-
itive selection via MACS using MicroBeads conjugated with a
monoclonal anti–rat CD8a antibody (clone G-28; Miltenyi Bio-
tec) according to the manufacturer’s instructions. Human mi-
crovascular endothelial cells (Cascade Biologics, Inc.) at passage
6–8 were seeded at a concentration of 2 
 

 
 10
 
5
 
 cells per well and
stimulated with 30 ng/ml recombinant human tissue necrosis fac-
tor-
 

 
 (TNF-
 

 
; R&D Systems). Isolated CTLs were incubated for
15 min at 37
 

 
C with 50 
 

 
M carboxyfluorescein diacetate succin-
imidyl ester (CFDASE; Molecular Probes). The fluorescent cells
were washed and incubated (8 
 

 
 10
 
5
 
 cells/ml, 100 
 

 
l per well)
with endothelial monolayers for 4 h, after which nonadherent
lymphocytes were removed and the endothelial monolayer was
washed. To examine whether the apoptosis is FasL-mediated, an
anti–mouse FasL antibody (clone MFL4; BD Biosciences) or an
isotype control antibody (BD Biosciences) was applied at 10 
 

 
g/
ml for 10 min at 37
 

 
C to the T cell suspension before the cocul-
ture. Cell death was assayed using the TUNEL procedure accord-
ing to the manufacturer’s instructions (Intergen). Apoptotic cells
were detected using a CD-330 charge-coupled device camera
(Dage-MIT) attached to an epifluorescence microscope (model
MZ FLIII; Leica). A minimum of eight fields each in three sepa-
rate experiments was analyzed per condition.
 
Morphometric and Statistical Analysis.
 
All results were expressed
as mean 
 

 
 SD. The number of leukocytes in each flat mount was
counted independently by two investigators under an epifluores-
cence microscope (DM RXA; Leica). The morphology of the
pathological neovascularization was readily discerned from the in-
traretinal extension of physiological vessels. The neovascular reti-
nal areas were photographed with an epifluorescence microscope
(MZ FLIII; Leica) and measured using NIH Image. The values
were processed for statistical analyses (Mann-Whitney U test).
Differences were considered statistically significant when the
P values were 
 
	
 
0.05.
 
Results
 
VEGF Expression in Physiological and Pathological Retinal
Neovascularization.
 
Absolute and relative VEGF isoform
expression levels were studied during both physiological
vascular development (Fig. 1, A and C) and pathological
neovascularization (Fig. 1, B and D). ELISA results showed
that retinal VEGF protein levels were approximately two-
fold higher in the pathologically neovascularizing retina
(Fig. 1 B) than in the developing retina undergoing physio-
logical neovascularization (Fig. 1 A). RT-PCR showed a
substantial relative difference in VEGF isoform expression
pattern between pathological (Fig. 1 D) and physiological
(Fig. 1 C) neovascularization. The VEGF
 
164
 
/VEGF
 
120
 
 ex-
pression ratio was calculated to be 2.2 
 

 
 1.1 in the physio-
logically developing retinas, and 25.3 
 

 
 8.7 in the patho-
logically neovascularized retinas.
 
Existence of Adherent Leukocytes at the Leading Edge of
Pathological, but Not Physiological, Retinal Neovasculariza-
tion.
 
Leukocyte adhesion was examined at the leading
edge of both physiological and pathological neovasculariza-
tion. Adherent leukocytes were largely absent at the lead-
ing edge of physiological postnatal retinal vascular develop-
ment (Fig. 2 A). In the retinopathy model of pathological
neovascularization (Fig. 2, B–F), a vast area of avascular ret-
ina was formed (Fig. 2 B) during exposure to the hyperoxic
environment (D0). Adherent leukocytes were found in the
revascularizing retina (Fig. 2 C) on D2. These leukocytes
were associated with the incipient pathological neovascular
fronds (Fig. 2 D) on D3. By D7, leukocytes were observed
in the areas of revascularization (Fig. 2 E), but were most
prominent in the pathological neovascular fronds extending
into the vitreous (Fig. 2 F).
 
Effect of VEGF
 
164
 
-specific Blockade on Physiological and
Pathological Retinal Neovascularization.
 
A VEGF
 
164(165)
 
 iso-
form-specific neutralizing aptamer (EYE001) was used to
determine the role of VEGF
 
164(165)
 
 in pathological neovas-
cularization. During pathological neovascularization (Fig.
3, A–F), VEGF
 
164
 
 blockade (Fig. 3 B) led to a significant
inhibition of leukocyte adhesion (Fig. 3 D) and pathologi-
cal neovascularization (Fig. 3 E). In contrast, little or no
suppression of revascularization (Fig. 3 F) and physiological
neovascularization (Fig. 3, G, H, and J) was observed.
Figure 1. Differential expression of VEGF isoforms during physiologi-
cal and pathological retinal neovascularization. (A) Retinal VEGF protein
levels (all isoforms) during postnatal development. (B) Retinal VEGF
protein levels after the induction (D0) of pathological neovascularization.
Dotted lines in A and B indicate the constitutive VEGF levels in normal
adult rats. (C) Retinal VEGF mRNA expression during postnatal devel-
opment. (D) Retinal VEGF mRNA expression after the induction of
pathological neovascularization. The relative expression levels of VEGF164
increased dramatically during pathological neovascularization.
T
h
e 
Jo
u
rn
al
 o
f 
E
xp
er
im
en
ta
l 
M
ed
ic
in
e
 
486
 
Leukocyte Roles in Ischemia-induced Retinal Neovascularization
 
When a VEGFR-1/Fc chimeric protein was used to com-
pare the neutralizing effects of the single VEGF
 
164
 
 isoform
versus all VEGF isoforms, VEGF pan-isoform blockade
(Fig. 3 C) resulted in a significant suppression of leukocyte
adhesion (Fig. 3 D) and pathological neovascularization
(Fig. 3 E). The result was similar to that seen with
VEGF
 
164
 
-specific blockade. However, in contrast to the
VEGF
 
164
 
 inhibition result, a significant suppression of re-
vascularization (Fig. 3 F) and physiological neovasculariza-
tion (Fig. 3, I and J) was observed with pan-isoform block-
ade. No difference was detected in physiological and
pathological neovascularization among the following con-
trol groups: nontreated, PEG-treated, and Fc-treated rats
(unpublished data). To further confirm the VEGF
 
164
 
 neu-
tralizing effect on retinal vascular development, VEGF
 
164
 
-
deficient mice were generated and evaluated. No differ-
ence in physiological neovascularization was detected
between wild-type (VEGF/) mice and VEGF164-defi-
cient (VEGF120/188) mice (Fig. 3, K–M).
Monocytes Are Positive Regulators of Pathological Retinal
Neovascularization. To investigate the role of monocytes
in pathological neovascularization, clodronate-liposomes
were used to inactivate monocyte lineage cells. Compared
with PBS-liposomes (Fig. 4 A), monocyte-selective deple-
tion (Fig. 4 B) led to a significant suppression of pathologi-
cal neovascularization (Fig. 4 C), but had negligible effect
on revascularization (Fig. 4 D). Immunohistochemistry
confirmed that a subset of the adherent leukocytes in the
vasculature (Fig. 4, E–J) were positive for CD13, ami-
nopeptidase N coexpressed with MHC-II for mono-
cyte-surface antigen processing. RT-PCR showed that
circulating monocytes isolated from rats with proliferative
retinopathy expressed VEGF120 and VEGF164, which was
markedly induced after hypoxic stimulation (Fig. 4 K).
T Lymphocytes Are Negative Regulators of Pathological Reti-
nal Neovascularization. To investigate the role of T lym-
phocytes in pathological neovascularization, a neutralizing
antibody against CD2 was used. CD2 is an important adhe-
sion molecule for T lymphocyte-mediated immune re-
sponses, and is also called lymphocyte function-associated
antigen-2 (LFA-2). Notably, compared with nonimmune
control IgG (Fig. 5 A), CD2 blockade (Fig. 5 B) led to sig-
nificant increase in the pathological neovascularization (Fig.
5 C). Immunohistochemistry confirmed that adherent leu-
Figure 2. Leukocytes are present at the leading edge of pathological,
but not physiological, retinal neovascularization. (A) No leukocyte adhe-
sion at the leading edge of physiological retinal development on P6. (B–
F) Leukocyte adhesion during the onset and progression of pathological
neovascularization. (B) The formation of extensive retinal ischemia on
D0, immediately after exposure to relative hypoxia (room air). (C)
Abundant inflammatory cells (arrows) randomly adhered to the intrareti-
nal vessels just before the onset of pathological neovascularization. (D)
The leukocyte adhesion (arrows) associated with the incipient vascular
budding on D3. (E) Compared with D0 (B), revascularization proceeded
in concert with pathological neovascularization (arrows) on D7. (F) Leu-
kocyte adhesion (arrows) spatially and temporally associated with vascular
budding. Bars: (A, C, D, and F) 50 m; (B and E) 0.5 mm.
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kocytes at the vascular fronds were positive for CD8 (Fig.
5, D–F) and CD25 (Fig. 5, G–I; IL-2 receptor), indicative
of cytotoxic and activated T lymphocytes, respectively. To
determine whether CD8-positive cytotoxic T lymphocytes
(CTLs) isolated from rats with retinopathy cause a FasL-
mediated endothelial cell apoptosis, cell death was evalu-
ated using a leukocyte–endothelial coculture system.
Compared with CTLs isolated from age-matched normal
control rats (Fig. 5 J), CTLs from rats with retinopathy
(Fig. 5 K) increased endothelial cell apoptosis (Fig. 5 N).
Administration of a FasL neutralizing antibody (Fig. 5 L),
but not a control nonimmune antibody (Fig. 5 M), led to
significant suppression of the apoptosis caused by the CTLs
isolated from the rats with retinopathy (Fig. 5 N).
Discussion
The current data demonstrate that pathological, but not
physiological, retinal neovascularization is characterized by
the overexpression, both in relative and absolute terms, of
the VEGF164 isoform. The hypoxia-induced VEGF164 iso-
form expression leads to the recruitment of leukocytes to
sites of pathological neovascularization. These data demon-
strate that ischemia-induced neovascularization, classically
thought to be noninflammatory in nature, is characterized
by the influx of inflammatory cells. 
Monocyte/macrophage lineage cells express VEGF re-
ceptor (R)-1 through which VEGF exerts its chemotactic
actions (6). VEGF also up-regulates the expression of
ICAM-1 on vascular endothelial cells in vitro (7). VEGF-
induced blood–retinal barrier breakdown was demon-
strated to be leukocyte-dependent, in part, when the in-
hibition of ICAM-1 prevented blood–retinal barrier
breakdown in VEGF165-injected rat eyes (8). In separate
studies, VEGF-induced endothelial ICAM-1 expression (9)
and vascular leakage (10) were shown to be mediated by
VEGFR-2. Thus, VEGF functions as a proinflammatory
cytokine targeting both leukocytes and endothelial cells.
Taking into account the differential affinity of the VEGF
isoforms for VEGF receptor binding (11, 12), VEGF165
seemed likely to be more responsible for the induction of
inflammation than VEGF121. 
The present work is the first to show that adherent leu-
kocytes are associated with the leading edge of pathological,
but not physiological, neovascularization (Fig. 2). The re-
Figure 3. Effect of VEGF164-specific blockade on physiological and
pathological retinal neovascularization. (A–F) VEGF164-specific blockade
versus VEGF pan-isoform blockade in pathological neovascularization.
(A) Pathological neovascularization (arrows, D7) treated with PEG control
(n 
 12) was not inhibited. (B) Pathological neovascularization (arrows,
D7) treated with the anti-VEGF165 aptamer (n 
 13). (C) Pathological
neovascularization (arrows, D7) treated with the VEGFR-1/Fc chimera
(n 
 10). In addition to the inhibition of leukocyte adhesion to the retinal
vasculature (D, P 	 0.01), pathological neovascular budding into the vit-
reous (E, PaNV) was significantly suppressed (P 	 0.01) via the anti-
VEGF164 aptamer or the VEGFR-1/Fc. In contrast, the effect of VEGF164
inhibition on physiological revascularization (F, PhRV) was negligible
(P  0.05), but pan-isoform inhibition led to significant suppression of
revascularization (F, P 	 0.01). Shaded bars indicate comparable values of
age-matched (P17) normal rat neonates (n 
 8). (G–J) VEGF164-specific
blockade versus VEGF pan-isoform blockade in retinal vascular develop-
ment. (G) Developing retinal vasculature (P10) treated with PEG control
(n 
 7). (H) Developing retinal vasculature (P10) treated with anti-
VEGF165 aptamer (n 
 8). (I) Developing retinal vasculature (P10) treated
with the VEGFR-1/Fc chimera (n 
 10). (J) Note the mild suppression
of physiological neovascularization during retinal development via
VEGF164 inhibition, but the substantial suppression via pan-isoform inhi-
bition (P 	 0.01). (K–M) VEGF164-specific deficiency versus wild type in
retinal vascular development. (K) Developing retinal vasculature (P10) in
wild-type control (VEGF/) mice (n 
 13). (L) Developing retinal vas-
culature (P10) in VEGF164-deficient (VEGF120/188) mice (n 
 13). (M)
VEGF164 deficiency had no significant effect on physiological neovascu-
larization (P  0.05). Bars: (K and L) 0.2 mm; (A–C and G–I) 0.5 mm.
Figure 4. Role of monocytes in patho-
logical retinal neovascularization. (A)
Pathological neovascularization (arrows,
D7) treated with PBS control-liposomes
(n 
 8) was not inhibited. (B) Pathological
neovascularization (arrows, D7) treated with
clodronate-liposomes (n 
 8). Notably, the
pathological neovascular budding (C,
PaNV) was suppressed (P 	 0.01), whereas
revascularization (D, phRV) was not (P 
0.05). (E–J) Monocyte adhesion was ob-
served just before and during pathological
neovascularization (H–J). Green fluores-
cence from the anti-CD13 antibody (E
and H) and red fluorescence from the
rhodamine-coupled Con A (F and I) identi-
fies the Con A–stained cells as being CD13-
positive leukocytes (arrows) when the im-
ages were superimposed (G and J). (K)
Monocyte VEGF mRNA expression in
normoxia (21% oxygen) and hypoxia (1%
oxygen). VEGF levels were markedly in-
creased in response to hypoxic stimulation.
Bars: (E–J) 50 m; (A and B) 0.5 mm.
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cruitment of leukocytes was largely suppressed via VEGF164
isoform-specific blockade (Fig. 3), directly implicating
VEGF164 in the process. Additionally, VEGF164, a more
proinflammatory isoform than VEGF120, was preferentially
induced in pathological neovascularization (Fig. 1). To-
gether, these observations indicate that leukocyte adhesion
in pathological, but not the physiological, neovasculariza-
tion is properly regarded as a VEGF164-induced pathology.
The current data also show that the selective depletion of
monocyte lineage cells in proliferative retinopathy sup-
presses pathological neovascularization, but not revascular-
ization (Fig. 4). The results mirror those seen after the
VEGF164-specific blockade (Fig. 3). Thus, inflammatory
monocytes appear to facilitate vitreous invasion by the ab-
errant vasculature. The VEGF164-mediated recruitment of
monocytes just before the appearance of pathological
neovascularization suggests that the monocytes may serve
to mark the sites of future neovascularization (Fig. 2). In-
deed, circulating monocytes have a pro-angiogenic poten-
tial expressing VEGF164, the production of which is mark-
edly enhanced by hypoxia (Fig. 4). The positive feedback
loop of VEGF164 and monocytes is a potential mechanism
leading to the amplification of pathological neovasculariza-
tion. Recent in situ hybridization data showing increased
VEGF expression in the ischemic retinal cells (3) and mac-
rophages (13) in the proliferative retinopathy model further
support our conclusions. 
VEGF164(165), an isoform more potently mitogenic (11) as
well as more proinflammatory than VEGF120(121), appears to
be sufficient for the physiological neovascularization of reti-
nal development (5). However, VEGF isoforms other than
VEGF164, in combination, may be sufficient to promote
normal physiological neovascularization. Indeed, the com-
plete inhibition of intracellular VEGF signaling was shown
previously to result in substantial suppression of normal vas-
cular development (3) and was reproduced here (Fig. 3),
whereas VEGF164-selective blockade did not affect normal
vascular development (Fig. 3). Consistent with these results,
retinal vascular development was normal in genetically
VEGF164-deficient mice expressing VEGF120 and VEGF188
(Fig. 3; VEGF120/188 mice) in agreement with the aptamer-
based VEGF164 neutralization data (Fig. 3). Consequently,
the expression pattern of the various VEGF isoforms,
strictly regulated during normal development but disrupted
in disease, is likely to contribute to an angiogenic switch,
converting the orderly intraretinal extension of vessels into
an inflammation-associated invasion of the vitreous.
The present paper shows that IL-2 receptor (CD25)-
positive cells and CD8-positive cells adhere to the patho-
logical neovascular fronds (Fig. 5), indicative of the pres-
ence of activated CTLs. In a murine tumor model, the
systemic administration of IL-12 and IL-2, both known to
activate cellular immunity, led to the recruitment of FasL-
positive CTLs and the inhibition of tumor neovasculariza-
tion and growth (14). Conversely, an angiogenic role of T
lymphocytes, a source of VEGF, has been suggested in hu-
man prostate cancer (15). The present paper demonstrates
that the inhibition of lymphocyte function results in the ag-
gravation of pathological neovascularization (Fig. 5). In our
model of pathological retinal neovascularization, CTL-
mediated cellular immunity is thought to play a critical role
in the defense against the ectopic proliferation of endothe-
lial cells. This is also supported by the findings that CD8-
positive T lymphocytes from rats undergoing pathological
neovascularization resulted in the FasL-mediated apoptosis
of endothelial cells in vitro (Fig. 5). The role of immuno-
therapy for retinal neovascular diseases is currently under
investigation.
Figure 5. Role of T lymphocytes in pathological retinal neovascular-
ization. (A) Pathological neovascularization (arrows, D7) treated with
nonimmune isotype control (n 
 9) showing a similar degree of patho-
logical vascular budding (arrows) compared with Fig. 2 E. (B) Pathologi-
cal neovascularization (arrows, D7) treated with anti-CD2 antibody (n 

11). Notably, the pathological neovascular budding (C, PaNV) was wors-
ened (P 	 0.01). (D–I) T cell subtypes in pathological neovascular buds.
Green fluorescence from the antibody against CD8 or CD25 (D and G)
and red fluorescence from the rhodamine-coupled Con A (E and H)
identifies the Con A–stained cells as being CD8- and CD25-positive leu-
kocytes (arrows) when the images were superimposed (F and I). (J–N)
Rhodamine-labeled apoptotic cells in the leukocyte–endothelial cocul-
tures were detected via TUNEL staining (red). CTLs were labeled with
CFDASE (green). Compared with control CTLs (J), retinopathy CTLs
(K) significantly increased the number of TUNEL-positive endothelial
cells (N, P 	 0.01). The process was significantly inhibited via FasL
blockade (L–N, n 
 18–24 in each condition, P 	 0.01). Bars: (D–I) 50
m; (J–M) 200 m; and (A and B) 0.5 mm.
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